Probing and Developing Hypoxia-Selective Anti-Cancer Agents

探索和开发缺氧选择性抗癌药物

• 批准号: DP0450122
• 负责人: Em/Prof Trevor Hambley
• 金额: $ 16.71万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-02-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0450122
• 关键词: Probing; Developing; Hypoxia; Selective; Anti

The development of compounds that are effective in the treatment of cancer and are less toxic than existing drugs depends on the selective targeting of tumours. Solid tumours have poorly oxygenated regions which represent unique chemical environments that can be targeted using selectively activated compounds. In this project we will develop the first in situ methods for monitoring the activation state in solid tumours to establish the selectivity of activation. These results will be used to tune the properties of two novel classes of selectively activated compounds and thereby develop agents able to treat the most problematic of cancers.

开发有效治疗癌症且毒性低于现有药物的化合物取决于肿瘤的选择性靶向。实体瘤具有氧合不良的区域，其代表可以使用选择性活化的化合物靶向的独特化学环境。在这个项目中，我们将开发第一个原位方法来监测实体瘤中的激活状态，以确定激活的选择性。这些结果将用于调整两种新型选择性活化化合物的性质，从而开发出能够治疗最有问题的癌症的药物。